Shockwave Medical, Inc. (“Shockwave”) owns U.S. Patent No. 8,956,371 (“the ’371 patent”). This patent is directed to the treatment of atherosclerosis through intravascular lithotripsy (“IVL”). The ...

Shockwave owns US Patent No. 8,956,371 (the “’371 patent”), which is directed to the treatment of atherosclerosis through intravascular lithotripsy. The claimed device is for a “typical over-the-wire ...

Adding balloon angioplasty to aggressive medical management significantly lowers the risk for stroke or death in patients with symptomatic intracranial atherosclerotic stenosis (sICAS), results of a ...

Please provide your email address to receive an email when new articles are posted on . Orbital atherectomy was no better than balloon angioplasty for treatment of certain severely calcified coronary ...

Results from the first randomized controlled trial to directly compare the safety and efficacy of cutting balloon (CB) angioplasty to intravascular lithotripsy (IVL) prior to drug-eluting stent (DES) ...

Balloon angioplasty is a minimally invasive procedure to treat blocked or narrowed arteries. It involves inserting a tiny balloon into a blood vessel and inflating it to treat blockages and improve ...

SANTA CLARA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified ...

WASHINGTON, DC – OCTOBER 29, 2024 – Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...